Product
Ponsegromab
Aliases
PF-06946860 high dose, PF-06946860 low dose, PF-06946860 medium dose, Placebo for ponsegromab
3 clinical trials
8 indications
Indication
Lung CancerIndication
Pancreatic CancerIndication
Colorectal CancerIndication
AnorexiaIndication
FatigueIndication
CachexiaIndication
Congestive Heart FailureIndication
HealthyClinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)Status: Active (not recruiting), Estimated PCD: 2024-03-13
Clinical trial
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILUREStatus: Recruiting, Estimated PCD: 2025-03-30
Clinical trial
A PHASE 1, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF PONSEGROMAB ADMINISTERED SUBCUTANEOUSLY IN HEALTHY ADULT CHINESE PARTICIPANTSStatus: Completed, Estimated PCD: 2023-07-07